A Hybrid Markov–SPC Approach to Assess Cost Differences in Urgent Care Utilization Using Patient-Reported Data in Inflammatory Bowel Disease
This new approach using PRO data and hybrid Markov-SPC analysis can analyze and visualize near real-time estimates of cost differences over time. Pending successful validation against a claims data standard, this approach could more comprehensively inform improvement, advocacy, and strategic planning efforts.
Authors
- Sarah Weaver (ORCID: https://orcid.org/0000-0002-2413-1879)
- Ridhima Oberai
- Gil Melmed (ORCID: https://orcid.org/0000-0002-2591-5165)
- Alice Kennedy (ORCID: https://orcid.org/0000-0002-4729-0282)
- Christopher V. Almario (ORCID: https://orcid.org/0000-0003-0664-9479)
- Brant J. Oliver (ORCID: https://orcid.org/0000-0002-7399-622X)
- James Testaverde
- Corey A. Siegel (ORCID: https://orcid.org/0000-0002-2240-6605)
Institutions
- Dartmouth College (US)
- Dartmouth Institute for Health Policy and Clinical Practice (US)
- Cedars-Sinai Medical Center (US)
- Dartmouth–Hitchcock Medical Center (US)
- Crohn's and Colitis Foundation (US)
- Dartmouth Health (US)
- Jönköping University (SE)
Publication Details
- Journal
- The Permanente Journal
- Published
- 2024-09-10
- DOI
- https://doi.org/10.7812/tpp/24.024
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Eli Lilly and Company
- Pfizer
- Biogen
- Samsung
- EMD Serono